Apellis Pharmaceuticals (NASDAQ:APLS) is gearing up to announce its quarterly earnings on Tuesday, 2024-11-05. Here's a quick overview of what investors should know before the release. Analysts are ...

In a preliminary report of its 2025 results, Apellis said sales of its geographic atrophy (GA) drug Syfovre came in at $587 million for the year, a 4% decline from its 2024 figure of $612 million. As ...

Apellis Pharmaceuticals is a Buy due to the significant FCF potential of SYFOVRE® and EMPAVELI®, with SYFOVRE® projected to exceed $1bn in annual sales by 2028. SYFOVRE® has shown efficacy in slowing ...

Across the recent three months, 15 analysts have shared their insights on Apellis Pharmaceuticals (NASDAQ:APLS), expressing a variety of opinions spanning from bullish to bearish. The table below ...

Apellis Pharmaceuticals, Inc. (NASDAQ:APLS) shares are moving lower Friday after the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency, following a re-examination, ...

Apellis Pharmaceuticals (NASDAQ:APLS) is preparing to release its quarterly earnings on Thursday, 2025-10-30. Here's a brief overview of what investors should keep in mind before the announcement.

Shares of Apellis Pharmaceuticals APLS have crashed 22.6% in the past week. The massive stock price decline was observed after the company reported preliminary fourth-quarter U.S. net product revenues ...